Modulation of Bax and mTOR for cancer therapeutics

A rationale exists for pharmacologic manipulation of the serine (S)184 phosphorylation site of the proapoptotic Bcl2 family member Bax as an anticancer strategy. Here we report the refinement of the Bax agonist SMBA1 to generate CYD-2-11, which has characteristics of a suitable clinical lead compoun...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Cancer Res
मुख्य लेखकों: Li, Rui, Ding, Chunyong, Zhang, Jun, Xie, Maohua, Park, Dongkyoo, Ding, Ye, Chen, Guo, Zhang, Guojing, Gilbert-Ross, Melissa, Zhou, Wei, Marcus, Adam I., Sun, Shi-Yong, Chen, Zhuo G., Sica, Gabriel L., Ramalingam, Suresh S., Magis, Andrew T., Fu, Haian, Khuri, Fadlo R., Curran, Walter J., Owonikoko, Taofeek K., Shin, Dong M., Zhou, Jia, Deng, Xingming
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2017
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5503158/
https://ncbi.nlm.nih.gov/pubmed/28381544
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-2356
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन